Last reviewed · How we verify
TRAFERMIN
TRAFERMIN is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | TRAFERMIN |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2016 |
Approved indications
Common side effects
Key clinical trials
- A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18 (PHASE3)
- The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study (PHASE3)
- The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study (PHASE3)
- A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3) (PHASE3)
- Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin) (PHASE3)
- A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan (PHASE2)
- Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRAFERMIN CI brief — competitive landscape report
- TRAFERMIN updates RSS · CI watch RSS